Chemical Treatment for Osteoporosis
- Detailed Technology Description
- Executive Summary In the United States alone, 10 million people are afflicted, and 18 million more are at risk of developing the bone disease, osteoporosis. The large market for osteoporosis treatments and the fact that currently available therapeutics have the potential to produce severe negative side effects or are required to be administered via injection. This demonstrates the need for new therapeutics that overcome these challenges. Description of Technology This technology uses high molecular weight polyethylene glycol (HMW-PEG) to treat osteoporosis. HMW-PEG has been previously shown to enhance GI mucinous and cytoskeletal barriers that prevent pathogenic gut bacteria from interacting with or invading the gut wall at points of weakness leading to systemic inflammation. Inflammation has been linked to bone loss leading to osteoporosis. Here, the inventor has demonstrated that HMW-PEG has positive effects on bone formation in mice. Key BenefitsMinimal side effects Easy delivery—orally takenPromotes bone formation ApplicationsOsteoporosis treatment Bone degeneration conditions Patent Status: PCT/US2014/028832 Licensing Rights Available Non-exclusive rights Inventors: Laura McCabe, Rifat Pamukcu Tech ID: TEC2013-0086 Alternative contact due to temporary leave: Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.
- *Abstract
-
None
- *Principal Investigator
-
Name: Laura McCabe, Professor
Department: Physiology
Name: Rifat Pamukcu, President & CEO
Department:
- Country/Region
- USA
For more information, please click Here
